H. Michael Shepard
2012
In 2012, H. Michael Shepard earned a total compensation of $1.7M as Vice President and Chief Scientific Officer at Halozyme Therapeutics, a 153% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $41,715 |
|---|---|
| Option Awards | $318,540 |
| Salary | $309,000 |
| Stock Awards | $1,066,273 |
| Other | $9,551 |
| Total | $1,745,079 |
Shepard received $1.1M in stock awards, accounting for 61% of the total pay in 2012.
Shepard also received $41.7K in non-equity incentive plan, $318.5K in option awards, $309K in salary and $9.6K in other compensation.
Rankings
In 2012, H. Michael Shepard's compensation ranked 4,021st out of 11,487 executives tracked by ExecPay. In other words, Shepard earned more than 65.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,021 out of 11,487 | 65th |
Division Manufacturing | 1,394 out of 4,253 | 67th |
Major group Chemicals And Allied Products | 315 out of 1,203 | 74th |
Industry group Drugs | 189 out of 925 | 80th |
Industry Biological Products, Except Diagnostic Substances | 35 out of 165 | 79th |
Source: SEC filing on April 7, 2014.
Shepard's colleagues
We found five more compensation records of executives who worked with H. Michael Shepard at Halozyme Therapeutics in 2012.
2012
Gregory Frost
Halozyme Therapeutics
Chief Executive Officer
2012
Kurt Gustafson
Halozyme Therapeutics
Chief Financial Officer
2012
James Shaffer
Halozyme Therapeutics
Former Vice President and Chief Commercial Officer
2012
Jean Liu
Halozyme Therapeutics
General Counsel
2012
David Ramsay
Halozyme Therapeutics